Keros Therapeutics, Inc.
General ticker "KROS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $576.1M (TTM average)
Keros Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -15.6%.
Estimated limits based on current volatility of 2.0%: low 10.91$, high 11.36$
Factors to consider:
- Total employees count: 78 (-53.8%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Need for additional capital, Clinical trial failure, Regulatory and compliance, Market competition, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [9.85$, 23.90$]
- 2026-12-31 to 2027-12-31 estimated range: [8.69$, 21.40$]
Financial Metrics affecting the KROS estimates:
- Positive: with PPE of 11.5 at the end of fiscal year the price was neutral
- Positive: Operating cash flow per share per price, % of 13.81 > 13.08
- Positive: Operating profit margin, % of 27.69 > 18.77
- Positive: Return on assets ratio (scaled to [-100,100]) of 20.47 > 6.06
- Positive: Shareholder equity ratio, % of 89.68 > 63.63
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating income (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term KROS quotes
Long-term KROS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.15MM | $3.55MM | $244.06MM |
| Operating Expenses | $170.09MM | $214.38MM | $176.49MM |
| Operating Income | $-169.94MM | $-210.83MM | $67.57MM |
| Non-Operating Income | $16.95MM | $23.78MM | $24.33MM |
| R&D Expense | $135.26MM | $173.63MM | $129.64MM |
| Income(Loss) | $-152.99MM | $-187.05MM | $91.90MM |
| Taxes | $0.00MM | $0.30MM | $4.88MM |
| Net Income(Loss)* | $-152.99MM | $-187.35MM | $87.01MM |
| Stockholders Equity | $332.21MM | $571.55MM | $303.13MM |
| Assets | $370.02MM | $615.89MM | $338.02MM |
| Operating Cash Flow | $-124.51MM | $-160.87MM | $107.50MM |
| Capital expenditure | $2.46MM | $1.93MM | $1.55MM |
| Investing Cash Flow | $-2.46MM | $-1.93MM | $-1.55MM |
| Financing Cash Flow | $178.96MM | $391.82MM | $-378.47MM |
| Earnings Per Share** | $-5.20 | $-5.00 | $2.34 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.